Our Vision is to become a global champion in chronic healthcare management
ALRT is dedicated to creating more effective chronic care management, sustainably providing measurable health information and enabling frequent patient/provider interactions, thus enhancing adherence to care plans, improving outcomes and containing healthcare costs.
Our Mission is to assist patients and healthcare providers (HCPs) improve diabetes outcomes and subscribers improve the quality of their healthcare offerings
We provide remote monitoring and care facilitation for diabetes patients utilizing a unique, FDA-cleared software platform. Our system enhances standard treatment methodologies and extends the capabilities of healthcare providers (HCPs).
ALRT Diabetes Solution is a remote care management platform that provides diagnostic tools for healthcare providers (HCPs) to optimize medications to improve outcomes.
Leadership
We’re not another cookie-cutter technology company developing basic applications that give diabetes patients suggestions on what they should be doing. We are a leading edge technology company at the intersection of patients, primary care doctors, endocrinologists, and big data that collects meaningful data, processes it with our proprietary algorithms and delivers actionable output instrumental in better disease management. It takes a special team of dedicated individuals with diverse backgrounds in diabetes, capital markets, entrepreneurship, healthcare, technology and finance to execute on this model, which is exactly what we’ve assembled to make ALRT a global presence.
Company Profile
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed a solution to assist veterinarians in determining the effectiveness of insulin and helping to identify the appropriate dose and frequency of administration for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.